When nonplatinum is the answer: The role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer

Nicoletta Colombo

doi:10.2217/fon-2017-0319

When nonplatinum is the answer: The role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer

Nicoletta Colombo

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Trabectedin + pegylated liposomal doxorubicin (PLD) offers a well tolerated and effective nonplatinum, nontaxane alternative for treatment of ovarian cancer patients with a treatment-free interval after platinum beyond 6 months, especially for those relapsing between 6 and 12 months and those who are not candidates to receive platinum-based therapy. Using the nonplatinum trabectedin + PLD combination gives patients time to recover from platinum-related toxicities and may restore platinum sensitivity in tumor cells. The sequence effect, by which intercalation of trabectedin + PLD between platinum regimens may enhance the activity of next platinum and improve survival, is currently under investigation in the Phase III prospective INternational OVArian cancer patients Trial with YONdelis.

Original language	English
Pages (from-to)	23-29
Number of pages	7
Journal	Future Oncology
Volume	13
Issue number	23S
DOIs	https://doi.org/10.2217/fon-2017-0319
Publication status	Published - Oct 1 2017

Keywords

recurrent ovarian cancer
sequence effect
trabectedin
treatment-free interval

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2017-0319

Fingerprint Dive into the research topics of 'When nonplatinum is the answer: The role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer'. Together they form a unique fingerprint.

Cite this

@article{a94ca254f05e4642b11b037b95ffa987,

title = "When nonplatinum is the answer: The role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer",

abstract = "Trabectedin + pegylated liposomal doxorubicin (PLD) offers a well tolerated and effective nonplatinum, nontaxane alternative for treatment of ovarian cancer patients with a treatment-free interval after platinum beyond 6 months, especially for those relapsing between 6 and 12 months and those who are not candidates to receive platinum-based therapy. Using the nonplatinum trabectedin + PLD combination gives patients time to recover from platinum-related toxicities and may restore platinum sensitivity in tumor cells. The sequence effect, by which intercalation of trabectedin + PLD between platinum regimens may enhance the activity of next platinum and improve survival, is currently under investigation in the Phase III prospective INternational OVArian cancer patients Trial with YONdelis.",

keywords = "recurrent ovarian cancer, sequence effect, trabectedin, treatment-free interval",

author = "Nicoletta Colombo",

year = "2017",

month = oct,

day = "1",

doi = "10.2217/fon-2017-0319",

language = "English",

volume = "13",

pages = "23--29",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "23S",

}

TY - JOUR

T1 - When nonplatinum is the answer

T2 - The role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer

AU - Colombo, Nicoletta

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Trabectedin + pegylated liposomal doxorubicin (PLD) offers a well tolerated and effective nonplatinum, nontaxane alternative for treatment of ovarian cancer patients with a treatment-free interval after platinum beyond 6 months, especially for those relapsing between 6 and 12 months and those who are not candidates to receive platinum-based therapy. Using the nonplatinum trabectedin + PLD combination gives patients time to recover from platinum-related toxicities and may restore platinum sensitivity in tumor cells. The sequence effect, by which intercalation of trabectedin + PLD between platinum regimens may enhance the activity of next platinum and improve survival, is currently under investigation in the Phase III prospective INternational OVArian cancer patients Trial with YONdelis.

AB - Trabectedin + pegylated liposomal doxorubicin (PLD) offers a well tolerated and effective nonplatinum, nontaxane alternative for treatment of ovarian cancer patients with a treatment-free interval after platinum beyond 6 months, especially for those relapsing between 6 and 12 months and those who are not candidates to receive platinum-based therapy. Using the nonplatinum trabectedin + PLD combination gives patients time to recover from platinum-related toxicities and may restore platinum sensitivity in tumor cells. The sequence effect, by which intercalation of trabectedin + PLD between platinum regimens may enhance the activity of next platinum and improve survival, is currently under investigation in the Phase III prospective INternational OVArian cancer patients Trial with YONdelis.

KW - recurrent ovarian cancer

KW - sequence effect

KW - trabectedin

KW - treatment-free interval

UR - http://www.scopus.com/inward/record.url?scp=85031721743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031721743&partnerID=8YFLogxK

U2 - 10.2217/fon-2017-0319

DO - 10.2217/fon-2017-0319

M3 - Article

AN - SCOPUS:85031721743

VL - 13

SP - 23

EP - 29

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 23S

ER -